OBJECTIVE:To evaluate the status quo and trend of the use of anticancer drugs in our hospital.METHODS:The anticancer drugs used in our hospital from July 2004 to June 2007 were analyzed in respect to the consumption sum and DDDs etc.RESULTS:The consumption sum of anticancer drugs increased year by year,with anticancer assistant drugs showing high proportion,and some new anticancer drugs derived from natural plants and antimetabolites have been increasingly used in the clinic.CONCLUSION:The variety of the anticancer drugs in our hospital is stable,and the anticancer drugs derived from natural plants,the monoclonal antibody medicine and the genetically engineered drug are expected to become the predominant therapy for cancer treatment.

OBJECTIVE:To evaluate the status quo and the tendency of three-stage analgestics for patients with cancer in our hospitals.METHODS:The use of three-stage analgestics for patients with cancer during the period2002～2005in our hospital were analyzed statistically in respect to consumption sum,DDDs and average daily costs,etc.RESULTS:The con-sumption sum and DDDs of three-stage analgesics increased year on year,of which,morphine and related drugs had gradually dominated the first places.The prices of sustained and controlled release preparations were high.CONCLUSION:The use of three-stage analgestics for patients with cancer in our hospital was rational on the whole,yet the application of three-stage analgestic therapy for pain relief in cancer patients should be further publicized.

Objective To investigate the usage of antibacterial drug in the department of operation in our hospital for improving the management and proper clinical utilization.Methods 1366 operational cases from our hospital were randomly collected from June 2004 to June 2005 and a comprehensive analysis of the usage of antibacterial drugs was conducted.Results All of the cases were given antibacterial drugs.The rate of preventive usage was 89.0%,among which those given in the period in 1h before operating was only 30.6%,and the other's was given after operating.The therapy time of antibacterial drugs were ranged from 1 to 63 days in different case and the preventive usage were 1 to 16 days.The therapy time of surpass 3 days was 94.7% and surpass 7 days was 53.5% in preventive usage.Prescriptions of more than one kind drug was widespread very much and 2～3 kinds were 87.5%.The wide-table,new-style and high-efficiency antibacterial drugs were the most frequently used in prescription.Conclusions The use of the antibacterial drugs in operational case in our hospital has some problem,especially in scope,opportunity moment,therapy time and union of usage.The management and education about rational usage of antibacterial drugs must be strengthened in order to improve the level of rationality in the clinical application.

Objective To assess and compare the incidence,clinical characteristics,treatment,and prognosis of acute heart failure patients from different grades hospitals in Beijing.Methods In this prospective internet prognosis registered study (Beijing AHF Registry),a total of 3 335 consecutive patients admitted to 14 emergency departments in Beijing from January 1st 2011 to September 23rd 2012 were enrolled.According to hospital grade,these patients were divided into two groups,349 patients were from secondary hospitals,and 2 956 patients were from tertiary hospitals.Results Among the 3 335 patients,the medium age was 71 (58,79) years,and male accounted for 53.16％.The most common underlying disease were coronary disease (43.27％),hypertension (17.73％),cardiomyopathy (16.07％) etc.The average treatment time in Emergency Department was 66.82 h.The emergency department mortality rate was 3.81％ (127 cases).The 30-day and 1-year cumulative all-cause mortality were 15.3％ and 32.27％,respectively.The 30-day and 1-year cumulative all-cause readmission were 15.64％ and 46.89％,respectively.Compared with patients in tertiary hospitals,patients in secondary hospitals had more onset acute heart failure patients (63.64％ vs.49.93％),shorter emergency department treatment time (12 h vs.41 h),lower discharge rate (3.43％ vs.37.45％) and emergency department mortality(1.58％ vs.4.09％).Compared with those in tertiary hospitals,1-year cumulative all-cause mortality (25.6％ vs.33.2％),cardiovascular disease mortality (20.2％ vs.26.0％),aggravated heart failure mortality (22.4％ vs.28.8％) were lower in secondary hospitals.Following propensity score matching,compared to tertiary hospitals,patients in secondary hospitals showed lower utilization rate of beta-blockers and ACEFARB (4.51％ vs.28.17％,1.41％ vs.9.58％),except the pironolactone.Conclusion Acute heart failure in emergency department is associated with a high mortality rate and readmission rate.There is still a big gap between guidelines recommend medication current treatments for acute heart failure.

BACKGROUND: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. METHODS: We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels. RESULTS: On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9% to 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3% to 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/145]). CONCLUSION: LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile. TRIAL REGISTRATION ClinicalTrials.gov, NCT04563936.
Humans ; Male ; Antineoplastic Agents, Hormonal/therapeutic use* ; East Asian People ; Gonadotropin-Releasing Hormone/agonists* ; Goserelin/therapeutic use* ; Prostate-Specific Antigen ; Prostatic Neoplasms/drug therapy* ; Testosterone